Valion Bio, Inc. — Form 8-K
Filed August 17, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 78/100
What the filing says
On August 17, 2026, Valion Bio received $1.5M from 3i, LP (Initial Closing) for 1,500 Series B Preferred Shares, contingent on CEO Michael Handley's removal. A second $1.5M closing is optional if parties execute a definitive side letter by August 24, 2026. Separately, Valion executed a 10-year royalty agreement with multiple payees (3i, LP and others) obligating Velocity Bioworks subsidiary to pay 5% of gross business revenue quarterly, with Valion guaranteeing payments. The royalty agreement has no dollar cap and runs through 2036.
Why this rating
Series B funding of $1.5M–$3M is substantial relative to $4M market cap (37.5–75% of equity value), but contingent on forced CEO change. Uncapped 10-year 5% royalty is long-term structural drag on subsidiary cash flow, reducing parent enterprise value permanently.
See more from August 17, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.